NDRA Stock Overview
Develops technologies to improve the capabilities of clinical diagnostic ultrasound. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
My Notes
Capture your thoughts, links and company narrative
ENDRA Life Sciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.62 |
| 52 Week High | US$4,882.50 |
| 52 Week Low | US$4.01 |
| Beta | 0.56 |
| 1 Month Change | 10.79% |
| 3 Month Change | -37.53% |
| 1 Year Change | -99.88% |
| 3 Year Change | -99.98% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
ENDRA to submit FDA De Novo request for liver disease monitoring system in coming weeks
Sep 29ENDRA Life Sciences receives European patent for TAEUS system
Aug 24Endra Life Sciences Q2 2022 Earnings Preview
Aug 12We're A Little Worried About ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate
Aug 08
We're Keeping An Eye On ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate
Nov 18We Think ENDRA Life Sciences (NASDAQ:NDRA) Needs To Drive Business Growth Carefully
Jul 19ENDRA Life Sciences names Irina Pestrikova Principal Financial Officer
Jun 15ENDRA Life Sciences granted 13th U.S. Patent for its TAEUS platform technology
Jan 13ENDRA Life Sciences renews GE Healthcare collaboration agreement
Dec 21Endra Life prices $5M-share offering
Dec 16Endra Life Sciences EPS beats by $0.02
Nov 16Shareholder Returns
| NDRA | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -3.1% | -3.6% | -4.0% |
| 1Y | -99.9% | 11.2% | 24.0% |
Return vs Industry: NDRA underperformed the US Medical Equipment industry which returned 12.2% over the past year.
Return vs Market: NDRA underperformed the US Market which returned 26.1% over the past year.
Price Volatility
| NDRA volatility | |
|---|---|
| NDRA Average Weekly Movement | 30.4% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: NDRA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NDRA's weekly volatility (30%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 21 | Alex Tokman | endrainc.com |
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company.
ENDRA Life Sciences Inc. Fundamentals Summary
| NDRA fundamental statistics | |
|---|---|
| Market cap | US$2.46m |
| Earnings (TTM) | -US$8.82m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs NDRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NDRA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$8.82m |
| Earnings | -US$8.82m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -16.42 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 3.2% |
How did NDRA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 11:23 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ENDRA Life Sciences Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Kyle Bauser | Colliers Securities |
| Vernon Bernardino | H.C. Wainwright & Co. |